Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology
- PMID: 31550176
- PMCID: PMC6874004
- DOI: 10.1200/CCI.19.00089
Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology
Abstract
Genomic testing has become a part of routine oncology care and plays critical roles in diagnosis, prognostic assessment, and treatment selection. Thus, in parallel, the variety of genomic testing providers and sequencing platforms has grown exponentially. Selection of the best-fit panel for each case can be daunting, with many factors to consider. Among them is whether alteration interpretation and therapy/clinical trial matching are included and/or sufficient. In this article, we review some common commercially available sequencing platforms for the genes and types of alterations tested, samples needed, and reporting content provided. We review publicly available resources for a do-it-yourself approach to alteration interpretation when it is not provided or when supplemental research is needed, along with resources to identify genomically matched treatment options that are approved and/or investigational. However, with both commercially provided interpretation and publicly available resources, there are still caveats and limitations that can stem from insufficient or ambiguous nomenclature as well as from the presentation of information. Use cases in which clinical decision making was affected are discussed. After treatment options are identified, it is important to assess the level of evidence for use within the patient's tumor type and molecular profile. However, numerous level-of-evidence scales have been published in recent years, so we provide a publicly available tool to facilitate interoperability. The level of evidence, along with other factors, such as allelic frequency and copy number, can be used to prioritize treatment options when multiple are identified.
Conflict of interest statement
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to
Jia Zeng
Dong Yang
Thuy Vu
Funda Meric-Bernstam
No other potential conflicts of interest were reported.
Figures

Similar articles
-
Precision Oncology Decision Support: Current Approaches and Strategies for the Future.Clin Cancer Res. 2018 Jun 15;24(12):2719-2731. doi: 10.1158/1078-0432.CCR-17-2494. Epub 2018 Feb 2. Clin Cancer Res. 2018. PMID: 29420224 Free PMC article. Review.
-
Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice.JCO Precis Oncol. 2021 May 20;5:PO.20.00513. doi: 10.1200/PO.20.00513. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34095711 Free PMC article. Review.
-
Physician interpretation of genomic test results and treatment selection.Cancer. 2018 Mar 1;124(5):966-972. doi: 10.1002/cncr.31112. Epub 2017 Nov 22. Cancer. 2018. PMID: 29165790 Free PMC article.
-
Enabling Precision Oncology Through Precision Diagnostics.Annu Rev Pathol. 2020 Jan 24;15:97-121. doi: 10.1146/annurev-pathmechdis-012418-012735. Annu Rev Pathol. 2020. PMID: 31977297 Review.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
Cited by
-
Actionability classification of variants of unknown significance correlates with functional effect.NPJ Precis Oncol. 2023 Jul 15;7(1):67. doi: 10.1038/s41698-023-00420-w. NPJ Precis Oncol. 2023. PMID: 37454202 Free PMC article.
-
Direct comparison shows that mRNA-based diagnostics incorporate information which cannot be learned directly from genomic mutations.BMC Bioinformatics. 2020 May 19;21(1):196. doi: 10.1186/s12859-020-3512-z. BMC Bioinformatics. 2020. PMID: 32429832 Free PMC article.
-
Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET.ESMO Open. 2025 Jun;10(6):105061. doi: 10.1016/j.esmoop.2025.105061. Epub 2025 Jun 2. ESMO Open. 2025. PMID: 40460677 Free PMC article.
-
PTEN pathogenic variants are associated with poor prognosis in patients with advanced soft tissue sarcoma.BJC Rep. 2024 Jan 30;2(1):9. doi: 10.1038/s44276-023-00029-3. BJC Rep. 2024. PMID: 39516677 Free PMC article.
-
Sex-dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma.Clin Cancer Res. 2024 Jan 17;30(2):413-419. doi: 10.1158/1078-0432.CCR-23-1990. Clin Cancer Res. 2024. PMID: 37831066 Free PMC article.
References
-
- O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13:417–430. - PubMed
-
- Freedman AN, Klabunde CN, Wiant K, et al. Use of next-generation sequencing tests to guide cancer treatment: Results from a nationally representative survey of oncologists in the United States. JCO Precis Oncol. 10.1200/PO.18.00169. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources